IP Library › Granted Patent US 10,590,179
Granted Patent B2
US 10,590,179 · App. 16/185,734 · Granted Mar 17, 2020

Peptide derived from GPC3, pharmaceutical composition for treatment or prevention of cancer using same, immunity inducer, and method for producing antigen-presenting cells

Inventors: Tomoya Miyakawa (Tokyo, JP); Masaaki Oka (Yamaguchi, JP); Shoichi Hazama (Yamaguchi, JP); Koji Tamada (Yamaguchi, JP); Keiko Udaka (Kochi, JP)
Assignee: Cytlimic Inc.
C07K14/4748A61K38/00A61K38/1764A61K39/00A61K39/0011A61P35/00A61P37/04C07K14/705A61K2039/572
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,590,179
App. No.
16/185,734
Granted
Mar 17, 2020
Kind
B2
Abstract

The present invention provides a peptide containing 8 or more consecutive amino acid residues in an amino acid sequence of any of SEQ ID NOS: 1 to 11 and consisting of 11 or less amino acid residues.

Claims (2)

1. A method for treating or preventing cancer in a subject, comprising administering to the subject a peptide comprising 8 or more consecutive amino acid residues but 11 or less amino acid residues of SEQ ID NO: 4.

2. The method of claim 1 , wherein the peptide can bind to one or more types of HLA molecules.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 12, 2023
From: CYTLIMIC INC.
To: NEC CORPORATION
Reel/Frame 062357/0203 →
Priority Claims (1)
JP 2015-046463 · Mar 9, 2015 · national
Continuity (2)
Division 15556694
Related Publication 20190062389A1 · Feb 28, 2019